| 000 | 01688 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515132218.0 | ||
| 264 | 0 | _c20081211 | |
| 008 | 200812s 0 0 eng d | ||
| 022 | _a1743-4300 | ||
| 024 | 7 |
_a10.1038/ncpcardio1309 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMoran, Andrew | |
| 245 | 0 | 0 |
_aEliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare? _h[electronic resource] |
| 260 |
_bNature clinical practice. Cardiovascular medicine _cOct 2008 |
||
| 300 |
_a606-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xeconomics |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xeconomics |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xeconomics |
| 650 | 0 | 4 |
_aAspirin _xeconomics |
| 650 | 0 | 4 |
_aCardiovascular Agents _xeconomics |
| 650 | 0 | 4 | _aComputer Simulation |
| 650 | 0 | 4 | _aCost Savings |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xeconomics |
| 650 | 0 | 4 |
_aInsurance, Pharmaceutical Services _xeconomics |
| 650 | 0 | 4 |
_aMedicare _xeconomics |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 |
_aMyocardial Infarction _xdrug therapy |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aGoldman, Lee | |
| 773 | 0 |
_tNature clinical practice. Cardiovascular medicine _gvol. 5 _gno. 10 _gp. 606-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/ncpcardio1309 _zAvailable from publisher's website |
| 999 |
_c18169812 _d18169812 |
||